A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

@article{Jonker2011API,
  title={A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.},
  author={Derek J. Jonker and Lee S. Rosen and Michael B Sawyer and Filippo Guglielmo de Braud and George Wilding and Christopher J. Sweeney and Gordon C. Jayson and Grant Mcarthur and Gordon Rustin and Glenwood Goss and Jeff Kantor and Leora Vel{\'a}squez and Shariq S Syed and O Mokliatchouk and David Feltquate and Georgia E. Kollia and Dimitry S. A. Nuyten and Susan M Galbraith},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 6},
  pages={1413-9}
}
BACKGROUND This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. PATIENTS AND METHODS Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range. The… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
23 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

The antiangiogenic activity in xenograft models of brivanib alaninate, a dual inhibitor of VEGFR-2 and FGFR-1 kinases

  • RS Bhide, LJ Lombardo, JT Hunt
  • Mol Cancer Ther 2010;
  • 2010

Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma ( HCC ) treated after transarterial chemoembolization ( TACE )

  • K Okita, N Imanaka, N Chida
  • J Clin Gastroenterol
  • 2009

Similar Papers

Loading similar papers…